37 results on '"Tumyan, Gayane"'
Search Results
2. Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study
3. Adrenal Insufficiency following Stereotactic Ablative Radiotherapy (SAbR) of Adrenal Gland Metastases.
4. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial
5. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study
6. ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma
7. PB1948: ACALABRUTINIB IN THE TREATMENT OF RICHTER SYNDROME
8. P639: ZANUBRUTINIB (ZANU) VS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EXTENDED FOLLOW-UP OF THE SEQUOIA STUDY
9. PB2259: THE NEW PD-1 INHIBITOR PROLGOLIMAB IN THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN’S LYMPHOMA
10. PB2309: OUTCOMES OF 22 PATIENTS WITH RELAPSED OR REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: SINGLE INSTITUTE EXPERIENCE
11. PSUN24 Adrenal Metastases Treated with Radiotherapy: Development of Adrenal Insufficiency
12. Treatment pathways and clinical outcomes in Hodgkin lymphoma outside Europe and North America: results from the international, multicenter, retrospective, B-HOLISTIC study
13. Zanubrutinib plus obinutuzumab (ZO) versus obinutuzumab (O) monotherapy in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the phase 2 randomized ROSEWOOD trial.
14. Sebaceous Carcinoma Masquerading As Orbital Cellulitis
15. A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström’s macroglobulinemia
16. Use of Positron Emission Tomography in Patients with Classical Hodgkin Lymphoma Outside of Europe and North America: Results from the International, Multi-Center, Retrospective B-Holistic Study
17. Results from the International, Multi-Center, Retrospective B-Holistic Study: Describing Treatment Pathways and Outcomes for Classical Hodgkin Lymphoma
18. Abstract #1003234: An Case of Severe Hypercalcemia from Progressive Disseminated Histoplasmosis in an Immunocompetent Adult
19. Diabetic Myonecrosis: A Rare Complication of Uncontrolled Diabetes Mellitus
20. A Case of Primary Hyperaldosteronism Presenting as Hemorrhagic Stroke
21. Acute Sterile Meningitis as a Primary Manifestation of Pituitary Apoplexy
22. Primary Analysis of the Tegar Study: A Phase II Study Exploring the Safety and Efficacy of Atezolizumab in Combination with Obinutuzumab or Rituximab in Patients with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), or Waldenstrom Macroglobulinemia (WM)
23. Long-Term Efficacy and Safety (27 months) of the Biosimilar CT-P10 in Patients with Low Tumor Burden Follicular Lymphoma
24. ELEVATE-TN Study. New data of acalabrutinib in first-line treatment of chronic lymphocytic leukemia. Resolution
25. SAT-LB54 Acute Sterile Meningitis as a Primary Manifestation of Pituitary Apoplexy
26. Mantle Cell Lymphoma: History, Current Principles of Diagnosis, and Treatment (Literature Review)
27. Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma
28. Long-Term Efficacy and Safety Results of CT-P10 and Reference Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma: Phase III Updated Study Results with Median Follow-up of 40 Months
29. Ibrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma in Community Clinical Practice Outside of Clinical Trials
30. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study
31. Interim Analysis Results from an International, Multi-Centre, Non-Interventional Retrospective Study to Describe Treatment Pathways, Outcomes, and Resource Use in Patients with Classical Hodgkin Lymphoma: B-CD30+ Hodgkin Lymphoma International Multi-Centre Retrospective Study of Treatment Practices and Outcomes (B-HOLISTIC)
32. Comparison of Efficacy and Safety of Biosimilar CT-P10 to Rituximab in Patients with Previously Untreated Low Tumor Burden Follicular Lymphoma (LTBFL): A Randomized Phase III Study
33. Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies
34. Primary Mediastinal (Thymic) Large B-Cell Lymphoma
35. Assessment of Measures to Reduce Infusion-Related Reactions in Patients with Chronic Lymphocytic Leukemia Treated with Obinutuzumab in the GREEN Study
36. Work-up and management of a high-risk patient with primary central nervous system lymphoma.
37. Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.